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A generation ago, it was suggested that the
threat of infectious diseases would soon become an
artifact of history. Today, as we approach the new
millennium, the folly of this position is
increasingly clear. My 87-year-old father recently
reminded me of this. In the course of his lifetime,
spent almost entirely in New York City, he has
witnessed two pandemics of extraordinary impact:
the global influenza pandemic of 1918–1919, which
killed more than 20 million people worldwide, and
the HIV/AIDS pandemic, which began to
accelerate in the early 1980s and continues
unabated in some parts of the world.  In addition,
at least 30 other new and reemerging diseases and
syndromes have been recognized since the 1970s,
including liver disease due to hepatitis C virus,
Lyme disease, foodborne illness caused by
Escherichia coli O157:H7 and Cyclospora, water-
borne disease due to Cryptosporidium, hantavirus
pulmonary syndrome, and human disease caused by
the avian H5N1 influenza virus (Figure 1). Clearly,
we remain vulnerable to new and reemerging
diseases.
New diseases are superimposed on endemic
diseases such as diarrheal diseases, malaria,
tuberculosis (TB), and measles, which continue
to exact a huge toll. Indeed, malaria and TB,
among others, are reemerging in a drug-resistant
form. Today, infectious diseases remain the leading
cause of death worldwide and the third leading
cause of death in the United States. Many
pathogens are becoming increasingly resistant
to standard antimicrobial drugs, making
treatment difficult and in some cases impos-
sible. Moreover, chronic conditions generally
considered noninfectious actually have been
found to have a microbial etiology.
Awareness of Emerging Infections
The challenges posed by infectious diseases
are recognized by the public and the media, as well
as by political leaders and policy makers at the
highest levels of government. There is a growing
awareness that we live a global community, that
diseases do not recognize borders, and that the
U.S. public health community has an important
role to play in fostering global health.
The Importance of Research
The infectious diseases community faces a
difficult challenge: coping with ongoing problems
such as malaria and TB while preparing for the
inevitable emergence of diseases that are
unknown or are recognized but will reemerge in a
more threatening form. Available resources must
be maximized by sustaining and increasing
collaboration between federal agencies, academia,
industry, and nongovernmental agencies, all of
which play important roles in the fight against
infectious diseases.
Within the federal government, the Centers
for Disease Control and Prevention’s (CDC) work
in detecting and tracking pathogens is critical,
especially with regard to diseases that have
recently emerged or have the potential for
emergence. Equally important, and complemen-
tary to CDC’s efforts, is basic and clinical research
supported by the National Institutes of Health
(NIH) and other agencies. Historically, basic
research has led to important, often serendipi-
tous, advances that have illuminated the etiology
of sometimes mysterious diseases and facilitated
the development of diagnostics, therapies, and
vaccines (Figure 2).
At the National Institute of Allergy and
Infectious Diseases (NIAID) at NIH, we have
increased funding for emerging diseases from
$39.3 million in fiscal year 1993 to an estimated
(president’s budget) $85.0 million in fiscal 1999
(Figure 3). Approximately 21% of the NIAID non-
AIDS infectious diseases budget is devoted to
emerging infectious diseases.
With the help of our advisory committees, we
have defined five priorities in emerging and
reemerging diseases research: 1) supporting the
application of relevant scientific knowledge and
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new technologies to the detection, identification,
and interdiction of emerging diseases, by expanding
research on ecologic and environmental factors
influencing disease emergence and transmission; 2)
supporting the application of recent discoveries and
new biomedical technologies to the identifica-
tion, management, and control of emerging
diseases, by expanding research on microbial
changes and adaptations that influence disease
emergence; 3) providing fundamental information
for developing prevention and treatment strate-
gies that can be employed to ameliorate disease
impact, by expanding research on host susceptibil-
ity to emerging or reemerging pathogens; 4)
supporting the development and validation of
vaccines, therapeutics, and other control
strategies for specific diseases with the potential
to emerge or reemerge; and 5) strengthening the
current U.S. research and training infrastructure
for detecting and responding to outbreaks of
infectious diseases.
Among many studies domestically and
internationally, NIAID sponsors five interna-
tional programs in tropical infectious diseases,
most of which have components both in the United
States and in the countries where the incidence of
these diseases is greatest. It is essential to
engage scientists in host countries and work
with them collaboratively, both to tap their
expertise as well as to help them build research
infrastructure on their home soil.
Successful Partnerships
The public and private sectors, including
government, academia, and industry, bring
complementary skills and perspectives to the
research endeavor. Cross-sector collaboration can
yield extraordinary dividends. A cogent example is
the development of protease inhibitors for the
treatment of HIV disease.
After HIV was identified in 1983, research-
ers funded by NIH and others began to
intensively study the structural and regulatory
genes of HIV and the role these genes and their
products play in the replication cycle of the
virus. This work led to an understanding of the
importance of the HIV protease enzyme and
methods to express, purify, and crystallize the
enzyme. Building on these findings, researchers
in the private sector designed and produced
specific inhibitors of HIV protease and worked
closely with the Food and Drug Administration,
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NIH, and others to assess protease inhibitors in
clinical trials.
The first of four licensed protease inhibitors
reached the market in December 1995. Given in
combination with at least two other antiretroviral
drugs, protease inhibitors dramatically reduce
levels of plasma viremia in a substantial proportion
of patients. Both controlled and observational
studies show that these potent regimens can provide
a substantial clinical benefit.
Although drug combinations that include
protease inhibitors have helped many patients, it
is far too soon to become complacent or declare
victory. Many patients have not benefited from the
new drugs or cannot tolerate their side effects, and
drug resistance will inevitably become more
widespread. The development of the next
generation of antiretroviral agents is crucial and
will require the skills of investigators in both the
public and private sectors. However, the cost of
antiretroviral drugs will probably keep them
beyond the reach of much of the developing world;
therefore, the development of an HIV vaccine is of
paramount importance.
Malaria Initiatives at NIH
Until relatively recently, AIDS was virtually
the only emerging disease with global impact that
was widely discussed in the United States;
however, other diseases such as malaria and TB
have actually caused more illnesses and deaths
over the past 2 decades.
Malaria kills up to three million persons each
year, most of them children in sub-Saharan Africa.
In the past year, NIH has worked with research
organizations and donor agencies from around the
world to form a coalition called the Multilateral
Initiative on Malaria. This unprecedented
initiative will enhance international collabora-
tions, encourage the involvement in malaria
research of scientists from malaria-endemic
countries, and identify additional malaria
research resources. In addition, NIH has
bolstered its long-term commitment to malaria
research. NIH-supported malaria projects—many
in collaboration with other government and
international agencies—include 1) a new reposi-
tory of materials available to researchers
worldwide; 2) basic, field-based, and clinical
research on all phases of malaria research; and 3)
projects to determine the genetic sequences of
important malaria species.
Responding to Avian H5N1 Influenza
An outbreak of avian H5N1 influenza in Hong
Kong recently alarmed the medical community
and the world. The multinational response to
this outbreak has involved the close collabora-
tion of many organizations (Figure 4). As part of
NIH’s long-standing research into respiratory
viruses, we had in our reagent repository the
specific antisera needed to quickly develop test
kits that were used effectively by CDC and
others for detecting and tracking the virus. We
also have supported the rapid production of a
recombinant vaccine against avian influenza
virus for use in laboratory and health-care
personnel at risk. Without a strong research
base, the rapid response to this emergency
would not have been possible.
Figure 2. Emerging infectious diseases: a research ap-
proach.
Figure 3. Emerging diseases funding (National Insti-
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Vaccine Development
With avian flu, malaria, AIDS, and other
new and reemerging diseases, an important goal
of NIH is the development of vaccines. If just
four recently developed vaccines (hepatitis B,
rotavirus, Haemophilus influenzae type b, and
acellular pertussis) were universally adminis-
tered, more than three million deaths could be
prevented each year.
Historically, scientific advances in microbiol-
ogy and related disciplines have driven the
development of new vaccines. For example, the
identification of microbial toxins, as well as
methods to inactivate them, allowed the
development of some of our earliest vaccines,
including those for diphtheria and tetanus. In the
1950s, new tissue culture techniques ushered in a
new generation of vaccines, including measles,
mumps, and rubella. In recent years we have seen
rapid advances in our understanding of the
immune system and host-pathogen interactions,
as well as technical advances such as recombinant
DNA technology, peptide synthesis, and gene
sequencing. Each of these has facilitated the
development of new vaccines and vaccine
candidates for important pathogens.
Sequence information can be used in many
ways and promises to be useful in identifying
antigens to incorporate into vaccines, as well as
determining the factors that influence the
antigenicity or virulence of a microbe. The
complete genetic sequences of more than 13
microorganisms have now been published. More
than 60 other sequencing projects for medically
important pathogens, such as Plasmodium spp.,
Mycobacterium spp., Chlamydia trachomatis, Vibrio
cholerae, and Neisseria gonorrhoeae, are under way.
Conclusion
The importance of basic research to the
control of emerging and reemerging diseases
cannot be overemphasized. Emerging diseases
research encompasses many disciplines, and
research advances that fall under the rubric of
emerging diseases will be relevant not only to
specific diseases being studied but to a broad range
of disciplines such as vaccinology, immunology,
and drug development (Figure 5). In turn,
research in these areas is critical to advances in
emerging and reemerging diseases. With a
sustained commitment to basic research and
cross-sector collaboration, important scientific
findings and technological advances can be
translated into improved global health and
reduced susceptibility to new microbial threats.
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